NO323780B1 - Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. - Google Patents
Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. Download PDFInfo
- Publication number
- NO323780B1 NO323780B1 NO20025756A NO20025756A NO323780B1 NO 323780 B1 NO323780 B1 NO 323780B1 NO 20025756 A NO20025756 A NO 20025756A NO 20025756 A NO20025756 A NO 20025756A NO 323780 B1 NO323780 B1 NO 323780B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- mixture
- water
- solvent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 116
- 238000000034 method Methods 0.000 title claims description 50
- 230000008569 process Effects 0.000 title claims description 10
- -1 pyrimidine compound Chemical class 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000001732 thrombotic effect Effects 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960004592 isopropanol Drugs 0.000 claims description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 150000001983 dialkylethers Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 3
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 33
- 238000002425 crystallisation Methods 0.000 description 14
- 230000008025 crystallization Effects 0.000 description 13
- 238000001819 mass spectrum Methods 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 239000003480 eluent Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 108091007262 P2T receptors Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VNSQXWISTNFYFV-UHFFFAOYSA-N 1,3-dioxol-4-ol Chemical compound OC1=COCO1 VNSQXWISTNFYFV-UHFFFAOYSA-N 0.000 description 1
- RZWHKKIXMPLQEM-UHFFFAOYSA-N 1-chloropropan-1-ol Chemical compound CCC(O)Cl RZWHKKIXMPLQEM-UHFFFAOYSA-N 0.000 description 1
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
- DDEDQHVHVPJFAC-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 DDEDQHVHVPJFAC-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040621 Shunt occlusion Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PPYPHCLFWPCGAU-UHFFFAOYSA-N methyl 2-(trifluoromethylsulfonyloxy)acetate Chemical compound COC(=O)COS(=O)(=O)C(F)(F)F PPYPHCLFWPCGAU-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229940019331 other antithrombotic agent in atc Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0013407.2A GB0013407D0 (en) | 2000-06-02 | 2000-06-02 | Forms of a chemical compound |
| PCT/SE2001/001239 WO2001092262A1 (en) | 2000-06-02 | 2001-05-31 | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20025756D0 NO20025756D0 (no) | 2002-11-29 |
| NO20025756L NO20025756L (no) | 2003-01-24 |
| NO323780B1 true NO323780B1 (no) | 2007-07-02 |
Family
ID=9892841
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025756A NO323780B1 (no) | 2000-06-02 | 2002-11-29 | Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. |
| NO20071547A NO332306B1 (no) | 2000-06-02 | 2007-03-23 | Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning |
| NO20120595A NO333289B1 (no) | 2000-06-02 | 2012-05-14 | Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071547A NO332306B1 (no) | 2000-06-02 | 2007-03-23 | Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning |
| NO20120595A NO333289B1 (no) | 2000-06-02 | 2012-05-14 | Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20030181469A1 (hu) |
| EP (3) | EP2292622A1 (hu) |
| JP (3) | JP5036947B2 (hu) |
| KR (1) | KR100781864B1 (hu) |
| CN (2) | CN1817883B (hu) |
| AR (2) | AR032335A1 (hu) |
| AT (2) | ATE555115T1 (hu) |
| AU (4) | AU6287401A (hu) |
| BG (3) | BG65837B1 (hu) |
| BR (1) | BR0111328A (hu) |
| CA (1) | CA2408596C (hu) |
| CY (1) | CY1113047T1 (hu) |
| CZ (2) | CZ307468B6 (hu) |
| DE (1) | DE60117972T2 (hu) |
| DK (2) | DK1493745T3 (hu) |
| EE (1) | EE05222B1 (hu) |
| ES (2) | ES2384708T3 (hu) |
| GB (1) | GB0013407D0 (hu) |
| HK (2) | HK1052347B (hu) |
| HU (2) | HU229374B1 (hu) |
| IL (4) | IL152777A0 (hu) |
| IS (2) | IS2609B (hu) |
| MX (1) | MXPA02011795A (hu) |
| MY (2) | MY140674A (hu) |
| NO (3) | NO323780B1 (hu) |
| NZ (1) | NZ522638A (hu) |
| PH (1) | PH12011000127A1 (hu) |
| PL (2) | PL359172A1 (hu) |
| PT (2) | PT1493745E (hu) |
| RU (3) | RU2325391C2 (hu) |
| SG (1) | SG135965A1 (hu) |
| SI (2) | SI1289992T1 (hu) |
| SK (1) | SK287817B6 (hu) |
| UA (1) | UA73181C2 (hu) |
| WO (1) | WO2001092262A1 (hu) |
| ZA (1) | ZA200209324B (hu) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| JP4298212B2 (ja) * | 2002-03-29 | 2009-07-15 | 大日本印刷株式会社 | 塩酸エピナスチン高融点型結晶の製造法 |
| WO2008024044A1 (en) * | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
| TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| JP2010508350A (ja) * | 2006-10-31 | 2010-03-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体 |
| KR101473207B1 (ko) * | 2007-04-13 | 2014-12-16 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법 |
| TWI496776B (zh) * | 2007-11-15 | 2015-08-21 | Astrazeneca Ab | 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法 |
| UA100864C2 (uk) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
| EP2340252B1 (en) | 2008-09-09 | 2015-11-11 | AstraZeneca AB | A process for preparing [1s- ]1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ]-3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino]- 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d]pyrimidin-3-yl]-5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates |
| CA2768043A1 (en) | 2009-07-27 | 2011-02-10 | Auspex Pharmaceuticals, Inc. | Cyclopropyl modulators of p2y12 receptor |
| MX2012006375A (es) * | 2009-12-03 | 2013-03-21 | Astrazeneca Ab | Co-cristales de un inhibidor de agregacion de plaquetas de triazolo [4, 5-d] pirimidina. |
| ES2548845T3 (es) * | 2009-12-23 | 2015-10-21 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico |
| CZ2011229A3 (cs) * | 2011-04-19 | 2012-08-15 | Zentiva, K.S. | Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy |
| CN103764149A (zh) * | 2011-06-01 | 2014-04-30 | 阿斯利康(瑞典)有限公司 | 新型替卡格雷共晶 |
| RU2014126351A (ru) * | 2011-11-30 | 2016-01-27 | Актавис Груп Птс Ехф | Новая кристаллическая форма тикагрелора и способ ее получения |
| EP2834247A4 (en) | 2012-04-05 | 2016-03-30 | Reddys Lab Ltd Dr | PREPARATION OF TICAGRELOR |
| WO2014000719A1 (en) | 2012-06-29 | 2014-01-03 | Zentiva, K.S. | Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol |
| CA2877541C (en) | 2012-07-04 | 2020-06-30 | Lek Pharmaceuticals D.D. | Ticagrelor adducts with divalent metal salts |
| CZ2012705A3 (cs) | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| CN103772393B (zh) * | 2012-10-18 | 2017-08-04 | 博瑞生物医药（苏州）股份有限公司 | 替卡格雷的晶型及其制备方法 |
| WO2014083139A1 (en) * | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
| CN103848836B (zh) * | 2012-12-07 | 2016-08-03 | 天津市汉康医药生物技术有限公司 | 替卡格雷倍半水合物及其制备方法 |
| WO2014118808A2 (en) * | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
| CZ307217B6 (cs) | 2013-03-14 | 2018-04-04 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru |
| WO2014155389A2 (en) * | 2013-03-25 | 2014-10-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of ticagrelor |
| CN104098570A (zh) * | 2013-04-07 | 2014-10-15 | 杭州领业医药科技有限公司 | 替卡格雷晶型及其制备方法和用途 |
| CN104098572A (zh) * | 2013-04-08 | 2014-10-15 | 博瑞生物医药技术(苏州)有限公司 | 替卡格雷共晶型 |
| CN104098553B (zh) * | 2013-04-10 | 2017-11-28 | 江苏恒瑞医药股份有限公司 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
| EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
| WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
| WO2014191321A1 (en) | 2013-05-29 | 2014-12-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
| CN106496234B (zh) * | 2013-06-03 | 2019-08-30 | 杭州领业医药科技有限公司 | 结晶形态的三唑[4,5-d]嘧啶化合物及其制备方法和用途 |
| EP3004113A2 (en) * | 2013-06-04 | 2016-04-13 | Dr. Reddy's Laboratories Ltd. | Preparation of ticagrelor |
| EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
| WO2015001489A1 (en) * | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
| CN104341423B (zh) * | 2013-08-02 | 2017-03-01 | 上海京新生物医药有限公司 | 替格瑞洛的一水合物及其制备方法与在制药中的应用 |
| CN104370912A (zh) * | 2013-08-13 | 2015-02-25 | 开原亨泰制药股份有限公司 | 替卡格雷多晶型体及其制备方法 |
| IN2013CH04023A (hu) * | 2013-09-10 | 2015-08-07 | Laurus Labs Pvt Ltd | |
| CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
| CN104650085A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 替卡格雷倍半水合物化合物 |
| CN103601726B (zh) * | 2013-12-02 | 2016-09-28 | 浙江大学 | 两种替格瑞洛药物共晶及其制备方法 |
| CN104710425B (zh) * | 2013-12-16 | 2019-06-14 | 石药集团中奇制药技术（石家庄）有限公司 | 一种替格瑞洛新结晶及其制备方法 |
| CN104650091B (zh) * | 2014-01-24 | 2016-10-05 | 福州乾正药业有限公司 | 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用 |
| CN104940204A (zh) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | 一种替格瑞洛固体制剂及其制备方法 |
| WO2015162537A1 (en) * | 2014-04-23 | 2015-10-29 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of ticagrelor |
| WO2015162630A1 (en) | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
| CN105315282B (zh) * | 2014-07-15 | 2018-09-21 | 博瑞生物医药（苏州）股份有限公司 | 一种制备替卡格雷无定型的方法 |
| WO2016016907A1 (en) * | 2014-08-01 | 2016-02-04 | Msn Laboratories Private Limited | Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol |
| US10017515B2 (en) | 2014-08-11 | 2018-07-10 | Sun Pharmaceutical Industries Limited | Stable amorphous ticagrelor and a process for its preparation |
| CN104193747B (zh) * | 2014-08-12 | 2016-05-11 | 许彩霞 | 替卡格雷无定形的制备 |
| WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
| CN105968113B (zh) * | 2015-03-12 | 2019-06-07 | 四川海思科制药有限公司 | 一种三唑并嘧啶衍生物及其应用 |
| WO2017072790A1 (en) * | 2015-10-26 | 2017-05-04 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of ticagrelor |
| US20190002471A1 (en) * | 2016-01-05 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | Crystalline Form Of Ticagrelor |
| IL262312B (en) | 2016-04-21 | 2022-08-01 | Astrazeneca Ab | Tablets containing ticagrelor that disintegrate upon oral administration and a process for their preparation |
| US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
| DK3292867T3 (da) * | 2016-09-09 | 2019-07-22 | Univ Liege | Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion |
| KR101916956B1 (ko) | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
| WO2018178997A1 (en) | 2017-03-31 | 2018-10-04 | Natco Pharma Limited | Novel crystalline form of ticagrelor |
| WO2019127294A1 (zh) * | 2017-12-29 | 2019-07-04 | 浙江天宇药业股份有限公司 | 一种纯化替格瑞洛的方法 |
| WO2019170244A1 (en) | 2018-03-08 | 2019-09-12 | Pharmaceutical Oriented Services Ltd. | Ticagrelor—containing tablet formulation |
| EP3829547A1 (en) | 2018-07-27 | 2021-06-09 | KRKA, d.d., Novo mesto | Pharmaceutical composition of ticagrelor |
| CN110194771A (zh) * | 2019-05-08 | 2019-09-03 | 北京济美堂医药研究有限公司 | 一种替格瑞洛药用ii晶型的制备方法 |
| CN114634489B (zh) * | 2022-04-19 | 2023-07-04 | 奎马特里克斯有限公司 | 结晶形式 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| US5747496A (en) | 1995-07-11 | 1998-05-05 | Astra Pharmaceuticals Limited | Inhibitors of platelet aggregation |
| EP0946561B1 (en) * | 1996-12-20 | 2002-02-13 | AstraZeneca AB | Triazolo(4,5-d)pyrimidinyl derivatives and their use as medicaments |
| TW530058B (en) * | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
| BR9811045A (pt) * | 1997-07-25 | 2000-08-22 | Gilead Sciences Inc | Composição de análogo de nucleotìdeo e processo de sìntese |
| TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| SE9904129D0 (sv) * | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
| GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
-
2000
- 2000-06-02 GB GBGB0013407.2A patent/GB0013407D0/en not_active Ceased
-
2001
- 2001-05-22 AR ARP010102432A patent/AR032335A1/es unknown
- 2001-05-31 SK SK1685-2002A patent/SK287817B6/sk not_active IP Right Cessation
- 2001-05-31 CZ CZ2012-293A patent/CZ307468B6/cs not_active IP Right Cessation
- 2001-05-31 SI SI200130541T patent/SI1289992T1/sl unknown
- 2001-05-31 EE EEP200200665A patent/EE05222B1/xx unknown
- 2001-05-31 MX MXPA02011795A patent/MXPA02011795A/es active IP Right Grant
- 2001-05-31 AT AT04015299T patent/ATE555115T1/de active
- 2001-05-31 HU HU0302284A patent/HU229374B1/hu unknown
- 2001-05-31 EP EP10182133A patent/EP2292622A1/en not_active Withdrawn
- 2001-05-31 IL IL15277701A patent/IL152777A0/xx unknown
- 2001-05-31 DK DK04015299.3T patent/DK1493745T3/da active
- 2001-05-31 US US10/296,990 patent/US20030181469A1/en not_active Abandoned
- 2001-05-31 SG SG200500599-6A patent/SG135965A1/en unknown
- 2001-05-31 PT PT04015299T patent/PT1493745E/pt unknown
- 2001-05-31 ES ES04015299T patent/ES2384708T3/es not_active Expired - Lifetime
- 2001-05-31 PL PL01359172A patent/PL359172A1/xx not_active IP Right Cessation
- 2001-05-31 PL PL392882A patent/PL392882A1/pl not_active Application Discontinuation
- 2001-05-31 EP EP01937109A patent/EP1289992B1/en not_active Expired - Lifetime
- 2001-05-31 WO PCT/SE2001/001239 patent/WO2001092262A1/en active Application Filing
- 2001-05-31 CZ CZ2002-3918A patent/CZ304347B6/cs not_active IP Right Cessation
- 2001-05-31 CN CN2006100025095A patent/CN1817883B/zh not_active Expired - Lifetime
- 2001-05-31 ES ES01937109T patent/ES2259031T3/es not_active Expired - Lifetime
- 2001-05-31 BR BR0111328-3A patent/BR0111328A/pt not_active Application Discontinuation
- 2001-05-31 CN CNB018105823A patent/CN1247583C/zh not_active Expired - Lifetime
- 2001-05-31 NZ NZ522638A patent/NZ522638A/en not_active IP Right Cessation
- 2001-05-31 DK DK01937109T patent/DK1289992T3/da active
- 2001-05-31 EP EP04015299.3A patent/EP1493745B2/en not_active Expired - Lifetime
- 2001-05-31 CA CA2408596A patent/CA2408596C/en not_active Expired - Lifetime
- 2001-05-31 KR KR1020027016379A patent/KR100781864B1/ko active IP Right Review Request
- 2001-05-31 JP JP2002500875A patent/JP5036947B2/ja not_active Expired - Lifetime
- 2001-05-31 DE DE60117972T patent/DE60117972T2/de not_active Expired - Lifetime
- 2001-05-31 AU AU6287401A patent/AU6287401A/xx active Pending
- 2001-05-31 RU RU2002135589/04A patent/RU2325391C2/ru active
- 2001-05-31 SI SI200131013T patent/SI1493745T1/sl unknown
- 2001-05-31 MY MYPI20012578A patent/MY140674A/en unknown
- 2001-05-31 AT AT01937109T patent/ATE320430T1/de active
- 2001-05-31 HU HU1300386A patent/HU230471B1/hu unknown
- 2001-05-31 PT PT01937109T patent/PT1289992E/pt unknown
- 2001-05-31 MY MYPI20092026A patent/MY148652A/en unknown
- 2001-05-31 UA UA20021210808A patent/UA73181C2/uk unknown
- 2001-05-31 AU AU2001262874A patent/AU2001262874B2/en not_active Expired
-
2002
- 2002-11-11 IL IL152777A patent/IL152777A/en active IP Right Grant
- 2002-11-15 ZA ZA200209324A patent/ZA200209324B/en unknown
- 2002-11-15 IS IS6623A patent/IS2609B/is unknown
- 2002-11-28 BG BG107331A patent/BG65837B1/bg unknown
- 2002-11-29 NO NO20025756A patent/NO323780B1/no not_active IP Right Cessation
-
2003
- 2003-06-24 HK HK03104536.0A patent/HK1052347B/zh not_active IP Right Cessation
-
2005
- 2005-06-16 HK HK05105060.9A patent/HK1073101A1/xx not_active IP Right Cessation
- 2005-08-30 RU RU2005127356/04A patent/RU2418802C2/ru active Protection Beyond IP Right Term
- 2005-10-03 US US11/240,801 patent/US7265124B2/en not_active Expired - Lifetime
-
2007
- 2007-03-05 AU AU2007200958A patent/AU2007200958B2/en active Active
- 2007-03-23 NO NO20071547A patent/NO332306B1/no not_active IP Right Cessation
- 2007-08-24 US US11/892,597 patent/US20070293513A1/en not_active Abandoned
- 2007-11-19 IL IL187482A patent/IL187482A/en active IP Right Grant
-
2008
- 2008-07-24 AR ARP080103205A patent/AR068086A2/es unknown
-
2009
- 2009-06-02 IS IS8825A patent/IS3019B/is unknown
- 2009-08-12 BG BG10110440A patent/BG66332B1/bg unknown
- 2009-12-07 IL IL202582A patent/IL202582A/en active IP Right Grant
-
2010
- 2010-12-10 RU RU2010150799/04A patent/RU2010150799A/ru not_active Application Discontinuation
- 2010-12-24 AU AU2010257449A patent/AU2010257449B2/en not_active Expired
-
2011
- 2011-04-19 PH PH12011000127A patent/PH12011000127A1/en unknown
- 2011-08-18 BG BG10111017A patent/BG111017A/bg unknown
-
2012
- 2012-05-01 JP JP2012104575A patent/JP5684192B2/ja not_active Expired - Lifetime
- 2012-05-14 NO NO20120595A patent/NO333289B1/no not_active IP Right Cessation
- 2012-06-21 CY CY20121100559T patent/CY1113047T1/el unknown
-
2014
- 2014-04-07 JP JP2014078665A patent/JP2014129423A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323780B1 (no) | Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. | |
| AU2001262874A1 (en) | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | |
| TWI330082B (en) | Crystalline form of triazolo(4,5-d)pyrimidine compound and method of preparing the same | |
| TW201034672A (en) | Mixture of crystalline forms of triazolo (4,5-D) pyrimidine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |